ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bulumtatug fuvedotin

Also written as “9MW2821”, “CVL006 in combination with 9MW2821” and “9MW2821+other anticancer therapy”.

Its studies are mostly in Triple Negative Breast Neoplasms · Carcinoma, Transitional Cell · Uterine Cervical Neoplasms, led by 2 companies.

Drug pageBulumtatug fuvedotin: every studyAll 16 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 12, 202313 company-led studies, 13 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Mabwell (Shanghai) Bioscienceits history only1212 open or runningphase 3since Dec 12, 2023Jan 19, 2022Dec 31, 2026phase 2 · NCT06079112
Convalife (Shanghai)11 open or runningphase 2since May 6, 2026May 6, 2026Apr 30, 2029phase 2 · NCT07615660

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Convalife (Shanghai) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named bulumtatug fuvedotinINNProposed as its International Nonproprietary Name in WHO's List 131
  2. May 6, 2026First study: phase 2 study in Advanced Solid TumorFirst studyNCT07615660 · 108 planned

Ahead

  1. Apr 30, 2029Primary completion: phase 2 study in Advanced Solid TumorNCT07615660

TargetBeta

NECTIN4 →read by rule
“An antibody drug conjugate (ADC) composed of bulumtatug, a humanized monoclonal antibody directed against the cell surface adhesion molecule and tumor-associated antigen (TAA) nectin-4 (PVRL4), site-specifically ”NCIt, by rule

Other programs on NECTIN4

ProgramCompanyFurthest phaseStudies
enfortumab vedotinruleAstellas Pharmaphase 420
notiretatug rezetecanJiangsu HengRui Medicinephase 314
Sutantatug EnvedotinruleCSPC Pharmaceutical Groupphase 36
zelenectide pevedotinrulebicycletx-limitedphase 25
Anti-nectin-4 Antibody-drug Conjugate MK-3120ruleMerckphase 25
Anti-nectin-4/Anti-TROP2 Bispecific Antibody-drug Conjugate AVZO-103ruleavenzo-therapeutics-incphase 21
Anti-nectin-4 Antibody-drug Conjugate IPH4502ruleinnate-pharmaphase 11
Anti-nectin-4/CD28 Bispecific Antibody RNDO-564rulerondo-therapeuticsphase 11
CT-202rulecontext-therapeutics-incphase 11

Studies

The one study Convalife (Shanghai) leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07615660Advanced Solid Tumor2Not yet recruitingApr 30, 2029108

How it is read

Names in the registry

  • “9MW2821”, 10 entries
  • “bulumtatug fuvedotin”, 2 entries
  • “CVL006 in combination with 9MW2821”, 2 entries
  • “9MW2821+other anticancer therapy”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.